Literature DB >> 28191361

Experimental Approaches for Eliminating Latent HIV.

Matthew D Marsden1, Jerome A Zack2.   

Abstract

Antiretroviral therapy (ART) can reduce HIV viral loads to undetectable levels and prevent disease progression. However, HIV persists in rare cellular reservoirs within ART-treated patients and rapidly reemerges if ART is stopped. Latently infected CD4+ T cells represent a major reservoir of HIV that persists during ART. Therefore, a cure for HIV must include methods that either permanently inactivate or eliminate latent virus. Experimental methods under investigation for eliminating latently infected cells include transplantation/gene therapy approaches intended to deplete the infected cells and replace them with HIV-resistant ones, and DNA editing strategies that are capable of damaging or excising non-expressing HIV proviruses. Alternatively, "activation-elimination," also known as "shock and kill," approaches aim to induce expression of latent virus, allowing the virus to be eliminated by viral cytopathic effects, immune effector mechanisms, or additional cells/antibodies that specifically target and kill cells expressing HIV proteins. Here, we describe these experimental approaches for eliminating latent HIV along with other recent advances in HIV cure research.

Entities:  

Keywords:  activation; latency; reservoir

Year:  2015        PMID: 28191361      PMCID: PMC5302864          DOI: 10.1615/forumimmundisther.2016015242

Source DB:  PubMed          Journal:  For Immunopathol Dis Therap        ISSN: 2151-8017


  53 in total

1.  HIV latency in the humanized BLT mouse.

Authors:  Matthew D Marsden; Michael Kovochich; Nuttee Suree; Saki Shimizu; Roshni Mehta; Ruth Cortado; Gregory Bristol; Dong Sung An; Jerome A Zack
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

2.  Molecular characterization, reactivation, and depletion of latent HIV.

Authors:  David G Brooks; Dean H Hamer; Philip A Arlen; Lianying Gao; Greg Bristol; Christina M R Kitchen; Edward A Berger; Jerome A Zack
Journal:  Immunity       Date:  2003-09       Impact factor: 31.745

Review 3.  HIV/AIDS eradication.

Authors:  Matthew D Marsden; Jerome A Zack
Journal:  Bioorg Med Chem Lett       Date:  2013-05-18       Impact factor: 2.823

4.  Intensification and stimulation therapy for human immunodeficiency virus type 1 reservoirs in infected persons receiving virally suppressive highly active antiretroviral therapy.

Authors:  Joseph Kulkosky; Giuseppe Nunnari; Miguel Otero; Sandra Calarota; Geetha Dornadula; Hui Zhang; Anne Malin; Julie Sullivan; Yan Xu; Joseph DeSimone; Timothy Babinchak; John Stern; Winston Cavert; Ashley Haase; Roger J Pomerantz
Journal:  J Infect Dis       Date:  2002-10-29       Impact factor: 5.226

5.  BET bromodomain inhibition as a novel strategy for reactivation of HIV-1.

Authors:  Camellia Banerjee; Nancie Archin; Daniel Michaels; Anna C Belkina; Gerald V Denis; James Bradner; Paola Sebastiani; David M Margolis; Monty Montano
Journal:  J Leukoc Biol       Date:  2012-07-16       Impact factor: 4.962

6.  Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy.

Authors:  T W Chun; L Stuyver; S B Mizell; L A Ehler; J A Mican; M Baseler; A L Lloyd; M A Nowak; A S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-25       Impact factor: 11.205

7.  HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation.

Authors:  Nicolas Chomont; Mohamed El-Far; Petronela Ancuta; Lydie Trautmann; Francesco A Procopio; Bader Yassine-Diab; Geneviève Boucher; Mohamed-Rachid Boulassel; Georges Ghattas; Jason M Brenchley; Timothy W Schacker; Brenna J Hill; Daniel C Douek; Jean-Pierre Routy; Elias K Haddad; Rafick-Pierre Sékaly
Journal:  Nat Med       Date:  2009-06-21       Impact factor: 53.440

8.  Lentiviral vectors encoding human immunodeficiency virus type 1 (HIV-1)-specific T-cell receptor genes efficiently convert peripheral blood CD8 T lymphocytes into cytotoxic T lymphocytes with potent in vitro and in vivo HIV-1-specific inhibitory activity.

Authors:  Aviva Joseph; Jian Hua Zheng; Antonia Follenzi; Teresa Dilorenzo; Kaori Sango; Jaime Hyman; Ken Chen; Alicja Piechocka-Trocha; Christian Brander; Erik Hooijberg; Dario A Vignali; Bruce D Walker; Harris Goldstein
Journal:  J Virol       Date:  2008-01-09       Impact factor: 5.103

9.  Generation of HIV latency in humanized BLT mice.

Authors:  Paul W Denton; Rikke Olesen; Shailesh K Choudhary; Nancy M Archin; Angela Wahl; Michael D Swanson; Morgan Chateau; Tomonori Nochi; John F Krisko; Rae Ann Spagnuolo; David M Margolis; J Victor Garcia
Journal:  J Virol       Date:  2011-10-19       Impact factor: 5.103

10.  Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations.

Authors:  Kai Deng; Mihaela Pertea; Anthony Rongvaux; Leyao Wang; Christine M Durand; Gabriel Ghiaur; Jun Lai; Holly L McHugh; Haiping Hao; Hao Zhang; Joseph B Margolick; Cagan Gurer; Andrew J Murphy; David M Valenzuela; George D Yancopoulos; Steven G Deeks; Till Strowig; Priti Kumar; Janet D Siliciano; Steven L Salzberg; Richard A Flavell; Liang Shan; Robert F Siliciano
Journal:  Nature       Date:  2015-01-07       Impact factor: 49.962

View more
  11 in total

1.  Interferon Alpha Enhances NK Cell Function and the Suppressive Capacity of HIV-Specific CD8+ T Cells.

Authors:  Abena K R Kwaa; Chloe A G Talana; Joel N Blankson
Journal:  J Virol       Date:  2019-01-17       Impact factor: 5.103

Review 2.  Getting the "Kill" into "Shock and Kill": Strategies to Eliminate Latent HIV.

Authors:  Youry Kim; Jenny L Anderson; Sharon R Lewin
Journal:  Cell Host Microbe       Date:  2018-01-10       Impact factor: 21.023

Review 3.  Nanotechnology approaches to eradicating HIV reservoirs.

Authors:  Shijie Cao; Kim A Woodrow
Journal:  Eur J Pharm Biopharm       Date:  2018-06-04       Impact factor: 5.571

Review 4.  Humanized Mouse Models for Human Immunodeficiency Virus Infection.

Authors:  Matthew D Marsden; Jerome A Zack
Journal:  Annu Rev Virol       Date:  2017-07-26       Impact factor: 10.431

5.  Prodrugs of PKC modulators show enhanced HIV latency reversal and an expanded therapeutic window.

Authors:  Jack L Sloane; Nancy L Benner; Katherine N Keenan; Xiaoyu Zang; Mohamed S A Soliman; Xiaomeng Wu; Melanie Dimapasoc; Tae-Wook Chun; Matthew D Marsden; Jerome A Zack; Paul A Wender
Journal:  Proc Natl Acad Sci U S A       Date:  2020-05-05       Impact factor: 11.205

6.  In vivo activation of latent HIV with a synthetic bryostatin analog effects both latent cell "kick" and "kill" in strategy for virus eradication.

Authors:  Matthew D Marsden; Brian A Loy; Xiaomeng Wu; Christina M Ramirez; Adam J Schrier; Danielle Murray; Akira Shimizu; Steven M Ryckbosch; Katherine E Near; Tae-Wook Chun; Paul A Wender; Jerome A Zack
Journal:  PLoS Pathog       Date:  2017-09-21       Impact factor: 6.823

7.  Characterization of designed, synthetically accessible bryostatin analog HIV latency reversing agents.

Authors:  Matthew D Marsden; Xiaomeng Wu; Sara M Navab; Brian A Loy; Adam J Schrier; Brian A DeChristopher; Akira J Shimizu; Clayton T Hardman; Stephen Ho; Christina M Ramirez; Paul A Wender; Jerome A Zack
Journal:  Virology       Date:  2018-05-26       Impact factor: 3.616

Review 8.  Regulation of Chemokines and Cytokines by Histone Deacetylases and an Update on Histone Decetylase Inhibitors in Human Diseases.

Authors:  Himavanth Reddy Gatla; Nethaji Muniraj; Prashanth Thevkar; Siddhartha Yavvari; Sahithi Sukhavasi; Monish Ram Makena
Journal:  Int J Mol Sci       Date:  2019-03-05       Impact factor: 5.923

9.  The inhibitor apoptosis protein antagonist Debio 1143 Is an attractive HIV-1 latency reversal candidate.

Authors:  Michael Bobardt; Joseph Kuo; Udayan Chatterji; Sumit Chanda; Susan J Little; Norbert Wiedemann; Gregoire Vuagniaux; Philippe A Gallay
Journal:  PLoS One       Date:  2019-02-04       Impact factor: 3.240

Review 10.  Diversity of small molecule HIV-1 latency reversing agents identified in low- and high-throughput small molecule screens.

Authors:  Pargol Hashemi; Ivan Sadowski
Journal:  Med Res Rev       Date:  2019-10-13       Impact factor: 12.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.